In vitro and in vivo effects of vanadate on K+-dependent phosphatase activities from subcellular fractions of brain, kidney and liver.
Inhibition of K+-dependent phosphatases by sodium orthovanadate was studied in the subcellular fractions of brain, kidney and liver from male Sprague-Dawley rats. The concentration required to produce an in vitro phosphatase inhibition of 50% ranged from a low of 0.2 microM in the kidney 900 X g fraction to a peak of 400 microM in the brain soluble fraction. The concentrations required to produce 50% inhibition occurred in the micromolar range for most fractions studied. Injection of sodium vanadate (i.p., 8 mg/kg) produced phosphatase inhibition in several of the fractions, but not as pronounced as the in vitro treatment. The results indicate that vanadate is a potent inhibitor of phosphatase activity in vitro, and may have similar potential in vivo.
Keller
R J
RJ
Sharma
R P
RP
D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000201:enzymology; D005452:Fluoresceins; D007274:Injections, Intraperitoneal; D007668:Kidney / Q000187:drug effects* / Q000201:enzymology; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D010744:Phosphoric Monoester Hydrolases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011188:Potassium; D051381:Rats; D014638:Vanadates; D014639:Vanadium / Q000633:toxicity*
D005452:Fluoresceins; D014639:Vanadium; D014638:Vanadates; D010744:Phosphoric Monoester Hydrolases; D011188:Potassium